IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St edges up as AI enthusiasm eases worries over higher oil prices, yields
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices ease as US-Iran truce hopes counter Saudi supply risk
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
AbbVie (ABBV) Reports Strong 3Q and Long term outlook; Cowen Reiterates Outperform
October 30, 2015 1:23 PM EDTCowen reiterated an Outperform rating and $77.00 price target on Abbvie (NYSE: ABBV) following the company's 3Q earnings results. Q3 EPS of $1.13 was $0.06 above consensus. Full year guidance has been raised to $4.26-4.28 (prior $4.10-4.30). Q3 sales of $5,944MM (+18%) were $54MM above... More
